MeSH D016773 - cutaneous leishmaniasis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| GE Healthcare | Meglumine, Metrizoic acid | Isopaque | 1982-01-01 | |||
| Knight Therapeutics | Miltefosine | Impavido | 2014-03-19 |
Clinical Trials
Historical Success Rate
Phase 1
75%3/4
Phase 2
83%10/12
Phase 3
31%4/13
Approved: 2Overall Success rate: 19%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use